Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05642442 · ClinicalTrials.gov registry record · Phase 2
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
NCT05642442 is a Phase 2 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 169 participants.
The verdict
NCT05642442, a Phase 2 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
Study Summary
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tasks.
Interventions
- DRUG Placebo
- DRUG Suvecaltamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2024-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05642442
The ClinicalTrials.gov registry entry for NCT05642442 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05642442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05642442 about?
NCT05642442 is a clinical study titled "A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease". This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target pop...
What is the current status of trial NCT05642442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2022-12-01. Estimated completion is 2024-11-11.
What interventions are being tested in trial NCT05642442?
The interventions under investigation include: Placebo (DRUG), Suvecaltamide (DRUG).
Who is sponsoring clinical trial NCT05642442?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.